Skip to main content
. 2022 Dec 25;15(1):124. doi: 10.3390/cancers15010124

Figure 2.

Figure 2

Cytokine array analysis of coculture supernatants during EGFR-TKI treatment. EGFR-mutant, EGFR-TKI (erlotinib)-sensitive cell lines (HCC 4006 and HCC827), EGFR wild-type, EGFR-TKI resistant cell line (A549), and EGFR-mutant, EGFR-TKI (erlotinib)-resistant cell line (H1975) indirectly cocultured with activated PBMC with or without erlotinib (10 nM for HCC827 and 40 nM for HCC4006, H1975, and A549) for 48 h. (A,B) CXCL10 (dot #4) was elevated after coculture, whereas erlotinib treatment had no effect on CXCL10 expression levels in HCC4006, HCC827, and H1975 cells. Spot densities from each membrane are described in Supplementary Table S1. (C,D) ELISA analysis of supernatants cocultured with activated PBMCs and two EGFR-mutant, EGFR-TKI-sensitive cell lines (HCC4006 and HCC827, respectively) during erlotinib treatment©. Data are presented as mean ± SD of three independent experiments. Statistical significance was determined with an unpaired Student’s t-test (* p < 0.05, ** p < 0.01 versus cultured HCC4006 cells or HCC827 cells alone, respectively).